⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL732717 | 0.77 | — | — | |
| SCHEMBL21138744 | 0.77 | — | — | |
| SCHEMBL2160172 | 0.74 | — | — | |
| SCHEMBL8384875 | 0.70 | — | — | |
| SCHEMBL30912804 | 0.70 | — | — | |
| SCHEMBL73805 | 0.69 | — | — | |
| SCHEMBL2132087 | 0.67 | — | — | |
| SCHEMBL3541977 | 0.67 | — | — | |
| SCHEMBL15332723 | 0.67 | — | — | |
| SCHEMBL270059 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801686-B | Insulin-oligomer conjugates, formulations and uses thereof | 比奥孔有限公司 | 2020-04-07 | — | — | CN | disclosed |
| EP-2626368-B1 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9102758-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| EP-1773878-B1 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | BIOCON LTD (IN) | 2015-03-04 | — | — | EP | disclosed |
| US-8563685-B2 | Fatty acid formulations and oral delivery of proteins and peptides, and uses thereof | BIOCON LIMITED (IN) | 2013-10-22 | — | — | US | disclosed |
| EP-2626368-A2 | Insulin-oligomer conjugates, formulations and uses thereof | Biocon Limited (IN) | 2013-08-14 | — | — | EP | disclosed |
| US-20110124553-A1 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2011-05-26 | — | — | US | disclosed |
| US-20110118179-A1 | CATION COMPLEXES OF INSULIN COMPOUND CONJUGATES, FORMULATIONS AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2011-05-19 | — | — | US | disclosed |
| US-7875700-B2 | polyoxyethylene glycol moieties; crystalline solid or a rod shaped crystal; proinsulin; pharmacokinetics; treating diabetes | BIOCON LIMITED (IN) | 2011-01-25 | — | — | US | disclosed |
| US-7872095-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2011-01-18 | — | — | US | disclosed |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2010-04-29 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| EP-1773878-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | Nobex Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014673-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | NOBEX CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | NOBEX CORPORATION | 2006-01-26 | — | — | US | disclosed |